Isotoosendanin

Synonyms: 异川楝素
Isotoosendanin 是一种具有口服活性的 TGFβR1 抑制剂,可抑制其激酶活性(IC50 = 6732 nM),通过直接靶向 SHP-2、增强其稳定性并减少其泛素化来抑制 JAK/STAT3 信号通路,从而抑制 TGF-β 诱导的三阴性乳腺癌(TNBC)细胞迁移、侵袭和转移,并在 TNBC 异种移植模型和 A549 异种移植肿瘤中显示出抗肿瘤活性,同时在醋酸诱导的血管通透性和 λ-角叉菜胶诱导的后爪水肿试验中表现出显著的抗炎效果,可用于非小细胞肺癌(NSCLC)、三阴性乳腺癌(TNBC)和炎症研究。
产品编号: MS-S26542 纯度: 99.51% CAS No.: 97871-44-8 分子式: C30H38O11 分子量: 574.62
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Isotoosendanin 是一种具有口服活性的 TGFβR1 抑制剂,可抑制其激酶活性(IC50 = 6732 nM),通过直接靶向 SHP-2、增强其稳定性并减少其泛素化来抑制 JAK/STAT3 信号通路,从而抑制 TGF-β 诱导的三阴性乳腺癌(TNBC)细胞迁移、侵袭和转移,并在 TNBC 异种移植模型和 A549 异种移植肿瘤中显示出抗肿瘤活性,同时在醋酸诱导的血管通透性和 λ-角叉菜胶诱导的后爪水肿试验中表现出显著的抗炎效果,可用于非小细胞肺癌(NSCLC)、三阴性乳腺癌(TNBC)和炎症研究。

生物实验数据

生物活性 Isotoosendanin is an orally active TGFβR1 inhibitor that inhibits its kinase activity (IC50 = 6732 nM) and suppresses the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability and reducing its ubiquitination, thereby inhibiting TGF-β-induced migration, invasion and metastasis of triple-negative breast cancer (TNBC) cells; it exhibits antitumor activity in TNBC xenograft models and A549 xenograft tumors, shows significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema assays, and can be used for research on non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and inflammation.
体外研究
(In Vitro)

Isotoosendanin (10-1000 nM,24 小时) 以浓度依赖方式减少 MDA-MB-231、BT549 和 4T1 三阴性乳腺癌 (TNBC) 细胞的伤口闭合、侵袭、侵袭足形成和迁移。
Isotoosendanin (300-1000 nM,24 小时) 通过降低 Vimentin、α-SMA、FSP1、Snail、ZEB1 表达,增加 E-cadherin 表达,并减少 Smad2/3 磷酸化,逆转 TGF-β 诱导的 MDA-MB-231、BT549 和 4T1 TNBC 细胞的上皮-间质转化 (EMT)。
Isotoosendanin (10-1000 nM) 直接与 TGFβR1 相互作用,抑制其激酶活性 (IC50 = 6732 nM),并减少其在 MDA-MB-231、BT549 和 4T1 TNBC 细胞中与 Smad2/3 的结合。
Isotoosendanin (0-90 μM,48-72 小时) 以剂量和时间依赖方式降低 A549、HCC827 和 H838 等非小细胞肺癌 (NSCLC) 细胞的活力,IC50 值范围为 1.691 至 18.20 µM。
Isotoosendanin (1-6 μM,72 小时) 显著抑制 A549、HCC827 和 H838 细胞的集落形成和增殖 (EdU 实验)。
Isotoosendanin (1-6 μM,24-72 小时) 在 A549、HCC827 和 H838 细胞中诱导 G0/G1 期阻滞,降低 CDK2 和 Cyclin D1/A2 的表达;促进细胞凋亡,增加 Bax 和 Cleaved Caspase-3 的表达,减少 Survivin 和非活性 Caspase-3 的表达。
Isotoosendanin (1-6 μM,72 小时) 以剂量依赖方式降低 A549、HCC827 和 H838 细胞中 STAT3 (Tyr705) 的磷酸化水平,抑制 STAT3 核转位,并抑制 IL-6/EGF 诱导的 STAT3 磷酸化以及 JAK2/3 和 TYK2 的磷酸化。

Cell Viability Assay

Cell Line: TGF-β-induced MDA-MB-231, BT549, and 4T1 TNBC cells
Concentration: 300, 1000 nM
Incubation Time: 24 h
Result: Decreased Vimentin, α-SMA, FSP1, Snail, ZEB1 expression.
Increased E-cadherin expression.
Reduced Smad2/3 phosphorylation.

Cell Cycle Analysis

Cell Line: A549, HCC827, and H838 cells
Concentration: 1, 2, 4, 6 μM
Incubation Time: 72 h
Result: Induced G0/G1 phase arrest in A549, HCC827, and H838 cells.

Apoptosis Analysis

Cell Line: A549, HCC827, and H838 cells
Concentration: 1, 2, 4, 6 μM
Incubation Time: 24 h
Result: Promoted cell apoptosis.
Increased the expression of Bax and Cleaved Caspase-3.
Decreased the expression of Survivin and inactive Caspase-3.

Western Blot Analysis

Cell Line: A549, HCC827, and H838 cells
Concentration: 1, 2, 4, 6 μM
Incubation Time: 72 h
Result: Reduced the phosphorylation level of STAT3 (Tyr705).
Inhibited STAT3 nuclear translocation.
Suppressed IL-6/EGF-induced STAT3 phosphorylation as well as JAK2/3 and TYK2 phosphorylation.
体内研究
(In Vivo)

Isotoosendanin (0.1-1 mg/kg,灌胃给药,每日一次,2 个月) 在 MDA-MB-231-luc-GFP 和 BT549-luc-GFP 异种移植模型中减少 TNBC 转移。
Isotoosendanin (1 mg/kg,灌胃给药,每日一次,2 个月) 在 TGFβR1 敲低的 MDA-MB-231 异种移植模型中与单独敲低相比无额外的抗转移作用,两者均减少转移并逆转 EMT。
Isotoosendanin (1 mg/kg,灌胃给药,每日一次,2 个月) 在 TGFβR1 过表达的 MDA-MB-231 异种移植模型中无法抑制转移和逆转 EMT。
Isotoosendanin (0.1-1 mg/kg,灌胃给药,每日一次,1 个月) 在 4T1-luc-GFP 异种移植模型中单独使用或联合抗 PD-L1 抗体时减少 TNBC 转移。
Isotoosendanin (10-20 mg/kg,腹腔注射,每两天一次,共 7 次) 显著减少 A549 异种移植肿瘤的生长。

Animal Model: MDA-MB-231-luc-GFP, BT549-luc-GFP or 4T1 cells (1×106 per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice
Dosage: 0.1, 1 mg/kg
Administration: i.g. daily for 2 months
Result: Reduced bioluminescence signal of metastases.
Decreased number of metastatic foci in liver and lung.
Reversed EMT in tumor tissues, with decreased Vimentin, α-SMA, FSP1 expression and increased E-cadherin expression.
Animal Model: MDA-MB-231-luc-GFP-shTGFbR1 cells (1×106 per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice
Dosage: 1 mg/kg
Administration: i.g. daily for 1 or 2 months
Result: Showed no additional reduction in bioluminescence signal of metastases compared to TGFbR1 knockdown alone at 1 mg/kg/day.
Showed no additional decrease in number of metastatic foci in liver and lung compared to TGFbR1 knockdown alone.
Showed no additional reversal of EMT in tumor tissues compared to TGFbR1 knockdown alone.
Animal Model: MDA-MB-231-luc-GFP-TGFbR1 cells (1×106 per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice
Dosage: 1 mg/kg
Administration: i.g. daily for 2 months
Result: Failed to reduce bioluminescence signal of metastases at 1 mg/kg/day (p.o., 2 months).
Failed to decrease number of metastatic foci in liver and lung.
Lost the ability to reverse EMT in tumor tissues.
Animal Model: 4T1 cells (1×106 per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice
Dosage: 0.1, 1 mg/kg
Administration: i.g. daily for 1 months
Result: Enhanced inhibition of tumor growth when combined with anti-PD-L1 at 1 mg/kg/day.
Prolonged survival time of mice compared to monotherapy.
Reduced collagen deposition in tumor microenvironment.
Promoted infiltration of TILs, DCs, and cytotoxic T cells (CD3+, Granzyme B+, CD107a+, CD8+ T cells) in tumor microenvironment.
Reversed EMT in tumor tissues more effectively than monotherapy.
Animal Model: A549 cells were subcutaneously injected into BALB/c nude mice (female, 4-5 weeks old, 18-20 g) to establish a xenograft model.
Dosage: 10, 20 mg/kg
Administration: i.p. once every two days for 7 times
Result: Reduced tumor volume and weight in A549 xenograft models.
Showed no significant change in mice body weight.
Increased expression of SHP-2, p-SHP-2 (Tyr542) and p-SHP-2 (Tyr580) in tumor tissues.
Decreased expression of p-STAT3 (Tyr705) and PCNA in tumor tissues.
Reduced expression of Cyclin D1, CDK2 and Survivin in tumor tissues.
Increased expression of Bax in tumor tissues.
性状 固体
颜色 White to off-white

化学信息

分子量 574.62
分子式 C30H38O11
CAS No. 97871-44-8
别名 异川楝素

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (43.51 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7403 mL8.7014 mL17.4028 mL43.5070 mL
5 mM0.3481 mL1.7403 mL3.4806 mL8.7014 mL
10 mM0.1740 mL0.8701 mL1.7403 mL4.3507 mL
15 mM0.1160 mL0.5801 mL1.1602 mL2.9005 mL
20 mM0.0870 mL0.4351 mL0.8701 mL2.1754 mL
25 mM0.0696 mL0.3481 mL0.6961 mL1.7403 mL
30 mM0.0580 mL0.2900 mL0.5801 mL1.4502 mL
40 mM0.0435 mL0.2175 mL0.4351 mL1.0877 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础